Loading
SB
Sesen Bio, Inc. Stock: price and insider trades · United States
Sesen Bio, Inc.: what insiders have been doing
Sesen Bio, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). The past year has been quiet: not a single insider filing for Sesen Bio, Inc. The previous disclosure was published on 8 October 2025.
Over the whole record (from 2016), the tally stands at no purchases and 53 sales.
For comparison within the same sector, see the insider buying recorded at Xenon Pharmaceuticals Inc. and Vivos Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
82
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€7M
53 ops. · all time
Who traded when
BuySaleMichael Klichinsky4 sales
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended December 2024 · cache
Income statement
Revenue17.4M
Net income-53.8M-308.6% margin
Last declaration on 8 October 2025
Declarations82 total
56,982 shares@ US$0.254210.5% of flowCommon StockSEC:0001104659-25-097928:1
56,982 shares@ €0.0944Common StockSEC:0001104659-25-097928:0
200,000 shares@ US$0.254336.6% of flowCommon StockSEC:0001104659-25-096740:1
119,347 shares@ US$0.260422.4% of flowCommon StockSEC:0001104659-25-096740:2
165,000 shares@ US$0.257100.0% of flowCommon StockSEC:0001104659-25-096740:0
319,991 sharesCommon StockSEC:0001104659-23-030748:1
50,000 sharesCommon StockSEC:0001104659-23-030748:2
51,250 sharesCommon StockSEC:0001104659-23-030748:0
2,297,546 sharesCommon StockSEC:0001104659-23-030751:0
2,215,877 sharesCommon StockSEC:0001104659-23-030752:0
12,175 sharesCommon StockSEC:0001104659-23-030746:0
484,347 sharesCommon StockSEC:0001104659-23-030750:0
413 sharesCommon stockSEC:0001104659-23-030747:0
183,317 shares@ US$0.58738.0% of flowCommon StockSEC:0001485003-23-000109:1
60,237 shares@ US$0.58712.5% of flowCommon StockSEC:0001485003-23-000109:2
102,975 shares@ US$0.58721.3% of flowCommon StockSEC:0001485003-23-000109:3
33,888 shares@ US$0.5877.0% of flowCommon StockSEC:0001485003-23-000109:4
606,800 shares@ US$0.58752.9% of flowCommon StockSEC:0001485003-23-000105:1
278,564 shares@ US$0.58724.3% of flowCommon StockSEC:0001485003-23-000105:2
190,375 shares@ US$0.58724.4% of flowCommon StockSEC:0001485003-23-000103:1
93,279 shares@ US$0.58712.0% of flowCommon StockSEC:0001485003-23-000103:2
180,750 shares@ US$0.58723.2% of flowCommon StockSEC:0001485003-23-000103:3
98,304 shares@ US$0.58712.6% of flowCommon StockSEC:0001485003-23-000103:4
185,000 shares@ US$0.58733.2% of flowCommon StockSEC:0001485003-23-000111:1
73,361 shares@ US$0.58713.2% of flowCommon StockSEC:0001485003-23-000111:2
25 of 82 declarations
About Sesen Bio, Inc.
Sesen Bio, Inc. is a U.S.-based biopharmaceutical company that was listed on the NASDAQ market in the United States (United States). The company was headquartered in Cambridge, Massachusetts, and built its identity around targeted fusion-protein therapeutics, with a strong focus on oncology. Its best-known development asset was Vicineum, also referred to as VB4-845, a locally administered targeted fusion protein designed for the treatment of non-muscle invasive bladder cancer (NMIBC). That focus placed Sesen Bio in a highly specialized niche of cancer drug development, where scientific differentiation can be meaningful but clinical and regulatory execution are decisive.
Founded in the 2000s, Sesen Bio was for most of its life a development-stage biotechnology company rather than a commercial-stage pharmaceutical group. In other words, its value proposition depended primarily on advancing one or more drug candidates through preclinical, clinical, and regulatory milestones. This is an important point for investors: companies like Sesen Bio typically have limited recurring revenue, a narrow product base, and high dependence on financing, data readouts, and strategic partnerships. Their equity performance is often driven more by milestone news than by operating fundamentals in the traditional sense.
Read moreShow less
From a competitive standpoint, Sesen Bio operated in one of the most crowded and capital-intensive areas of healthcare. Oncology drug development is dominated by large multinational pharmaceutical companies, well-funded biotech peers, and alternative technology platforms such as immunotherapy, antibody-drug conjugates, and cell therapy. Sesen Bio’s competitive edge was its targeted fusion-protein approach, which aimed to improve tumor selectivity and potentially reduce off-target toxicity. However, in biotech, scientific promise must be translated into robust clinical data and a viable regulatory path to create sustainable shareholder value.
A major recent development was the company’s strategic review and subsequent merger process with Carisma Therapeutics. The transaction closed in March 2023, which significantly changed the company’s strategic profile and market narrative. As a result, Sesen Bio should be viewed less as a standalone late-stage oncology developer and more as a company whose recent history is defined by restructuring, strategic alternatives, and a transformative business combination. For investors in the French, Belgian, and Swiss markets, the case illustrates the typical U.S. small-cap biotech risk/reward equation: high optionality, limited visibility, and strong dependence on corporate events rather than established commercial cash flows.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
